Johnson Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Johnson Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Sell	468 -10	-2%	-$6.81K	﹤0.01%	738
2026 Q1	$370K	Buy	478 +15	+3%	+$11.5K	﹤0.01%	672
2025 Q4	$357K	Hold	463	–	–	﹤0.01%	625
2025 Q3	$260K	Hold	463	–	–	﹤0.01%	727
2025 Q2	$243K	Sell	463 -23	-5%	-$12.8K	﹤0.01%	721
2025 Q1	$308K	Sell	486 -1	-0.2%	-$688	﹤0.01%	635
2024 Q4	$347K	Buy	487 +207	+74%	+$174K	﹤0.01%	611
2024 Q3	$294K	Buy	280 +55	+24%	+$61.2K	﹤0.01%	645
2024 Q2	$236K	Hold	225	–	–	﹤0.01%	665
2024 Q1	$217K	Buy	+225	New	+$214K	﹤0.01%	696
2023 Q4	–	Sell	-340	Closed	-$280K	–	731
2023 Q3	$280K	Sell	340 -740	-69%	-$582K	﹤0.01%	574
2023 Q2	$776K	Sell	1,080 -10	-0.9%	-$7.71K	0.01%	396
2023 Q1	$896K	Buy	1,090 +15	+1%	+$11.3K	0.01%	368
2022 Q4	$776K	Sell	1,075 -96	-8%	-$70.8K	0.01%	382
2022 Q3	$807K	Buy	1,171 +24	+2%	+$15.1K	0.01%	361
2022 Q2	$678K	Buy	1,147 +79	+7%	+$51.4K	0.01%	391
2022 Q1	$746K	Buy	1,068 +47	+5%	+$29.7K	0.01%	398
2021 Q4	$645K	Sell	1,021 -5	-0.5%	-$3.07K	0.01%	409
2021 Q3	$621K	Buy	1,026 +19	+2%	+$11.8K	0.01%	404
2021 Q2	$562K	Buy	1,007 +4	+0.4%	+$2.03K	0.01%	418
2021 Q1	$475K	Buy	1,003 +30	+3%	+$14.6K	0.01%	433
2020 Q4	$470K	Buy	973 +3	+0.3%	+$1.62K	0.01%	409
2020 Q3	$543K	Hold	970	–	–	0.01%	374
2020 Q2	$605K	Sell	970 -250	-20%	-$142K	0.01%	361
2020 Q1	$596K	Sell	1,220 -24	-2%	-$9.9K	0.01%	334
2019 Q4	$467K	Sell	1,244 -78	-6%	-$26.2K	0.01%	428
2019 Q3	$367K	Sell	1,322 -60	-4%	-$17.8K	0.01%	464
2019 Q2	$432K	Buy	1,382 +547	+66%	+$182K	0.01%	449
2019 Q1	$342K	Buy	+835	New	+$344K	0.01%	478

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Johnson Investment Counsel's REGN Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q2 2026, selling an estimated $6.81K and leaving 468 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Johnson Investment Counsel first reported a position in REGN in Q1 2019 and has held it in 29 quarters since. The position peaked at $896K in Q1 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Johnson Investment Counsel held 468 shares of Regeneron Pharmaceuticals worth $292K as of Q2 2026.
Johnson Investment Counsel sold 10 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.81K.
Regeneron Pharmaceuticals made up ﹤0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #738 holding.
Johnson Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
Johnson Investment Counsel's Regeneron Pharmaceuticals position peaked at $896K in Q1 2023.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.